Royalty Pharma PLC (NAS:RPRX)
$ 26.6 0.31 (1.18%) Market Cap: 11.82 Bil Enterprise Value: 17.66 Bil PE Ratio: 10.43 PB Ratio: 1.73 GF Score: 79/100

Q3 2020 Royalty Pharma PLC Earnings Call Transcript

Nov 11, 2020 / 01:00PM GMT
Release Date Price: $40.31 (-0.71%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Royalty Pharma Third Quarter 2020 Earnings Conference Call. I would now like to turn the call over to George Grofik, Senior Vice President, Head of Investor Relations and Communications. Please go ahead, sir.

George Grofik

Thank you, Shannon, and good morning, good afternoon to everyone on the call. Thank you for joining us to review Royalty Pharma's third quarter results. You can find the slides of this call on the Investors page of our website at royaltypharma.com.

Moving to Slide 3, I would like to remind you that information presented in this call contain forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. I refer you to our S-1 prospectus on file with the SEC for a description of these risk factors.

And with that, please advance to Slide 4. Our speakers on the call today are Pablo Legorreta Founder and Chief Executive Officer; Jim Reddoch, EVP, Head of Research and Investments; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot